Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a New Technique -IN-REC-SUR-E- in Preterm Neonates With RDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. In-Born at 24+0-27+6 (and)~2. Spontaneously breathing at birth but requiring respiratory support (CPAP or O2) at 5' of life (and)~3. Parental consent has been obtained (and)~4. Failing nCPAP during the first 24 hours of life~Exclusion Criteria:~1. Severe birth asphyxia or a 5-minute Apgar score \<3~2. Endotracheal intubation in the delivery room for resuscitation or insufficient respiratory drive according to AAP guidelines16~3. Prolonged PROM \> 3 weeks~4. Presence of major congenital malformations~5. Hydrops fetalis~6. Inherited disorders of metabolism

- Gender: ALL
- Minimum Age: 24 Weeks
- Maximum Age: 27 Weeks
- Healthy Volunteers: f

Study Arms:
- INRECSURE (Type: EXPERIMENTAL): Infants in the INRECSURE arm will undergo the following approach: as soon as possible after the recruitment manoeuver (at CDP-Optimal) a dose of poractant alfa (Curosurf \[Chiesi Farmaceutici, Parma, Italy\]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. A temporary reduction of frequency may be necessary to increase the VT up to 2.5 ml/kg for improving the surfactant spreading.
- INSURE (Type: ACTIVE_COMPARATOR): Infants in the INSURE arm will undergo the following approach: after intubation, a dose of poractant alfa (Curosurf \[Chiesi Farmaceutici, Parma, Italy\]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. During surfactant administration, infants will be manually ventilated to facilitate surfactant distribution.

Based on this trial design, predict the completion outcome and termination type (if applicable).